Impact of insulin-sensitizing agents on risk for liver cancer and liver-related death in diabetic patients with compensated hepatitis C cirrhosis

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 8, 2011, Pages 2398-2400

  Popov, Violeta B ^a   Lim, Joseph K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; PEGINTERFERON; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RIBAVIRIN; SULFONYLUREA DERIVATIVE;

CAUSE OF DEATH; DIABETES MELLITUS; DISEASE SEVERITY; DRUG RESPONSE; EDITORIAL; EPIDEMIOLOGICAL DATA; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIVER CANCER; LIVER CIRRHOSIS; METABOLIC SYNDROME X; MORTALITY; OBESITY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION;

DIABETES MELLITUS, TYPE 2; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; METFORMIN;

HEPATITIS C VIRUS;

EID: 79961234522     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1875     Document Type: Editorial

References (21)

1. Rosen HR 2011 Chronic hepatitis C infection. N Engl J Med 364: 2429-2438
2. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, Richardson P, El-Serag HB 2011 Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C infection. Gastroenterology 140:1182-1188.e1
3. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW 2010 Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138:513-521
4. Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, Nagao Y, Yanagimoto C, Hanada S, Koga H, Sata M 2007 Clearance of HCV improves insulin resistance, B-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 102:570-576 (Pubitemid 46328143)
5. Bugianesi E, McCullough AJ, Marchesini G 2005 Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42:987-1000 (Pubitemid 43112663)
6. Lamb P, Harrison S 2010 Metabolic syndrome and HCV: where do we stand in 2010? Curr Hepat Rep 9:133-139
7. Hung CH, Wang JH, Hu TH, Chen CH, Chang KC, Yen YH, Kuo YH, Tsai MC, Lu SN, Lee CM 2010 Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol 16:2265-2271
8. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA 29 April 2011 Metabolic syndrome increases the risk of primary liver cancer in the United States: a population-based casecontrol study. Hepatology 10.1002/hep.24397
9. Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, Li G, Wang L 4 May 2011 Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer 10.1002/ijc.26165
10. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ 2004 Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160-1167 (Pubitemid 38747263)
11. Saito K, Inoue S, Saito T, Kiso S, Ito N, Tamura S, Watanabe H, Takeda H, Misawa H, Togashi H, Matsuzawa Y, Kawata S 2002 Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma. Gut 51:100-104 (Pubitemid 34717752)
12. Currie CJ, Poole CD, Gale EA 2009 The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52: 1766-1777
13. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD 2005 Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304-1305 (Pubitemid 40813563)
14. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ 2010 Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33:322-326
15. Dowling RJ, Goodwin PJ, Stambolic V 2011 Understanding the benefit of metformin use in cancer treatment. BMC Med 9:33
16. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG 2010 Metformin: taking away the candy for cancer? Eur J Cancer 46:2369-2380
17. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI 1998 Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867-872 (Pubitemid 28135963)
18. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI 2000 Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49:2063-2069
19. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G 2010 Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 30:750-758
20. Chen TM, Lin CC, Huang PT, Wen CF 2011 Metformin associated with lower mortality in diabetic patients with early stage HCC after radiofrequency ablation. J Gastroenterol Hepatol 26:858-865
21. Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, Ganne-Carrie N, Grando-Lemaire V, Vicaut E, Trinchet JC, Beaugrand M 2011 Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 96:2601-2608